Cinobac
Cinobac Uses, Dosage, Side Effects, Food Interaction and all others data.
Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Cinobac is a synthetic antibacterial agent with in vitro activity against many gram-negative aerobic bacteria, particularly strains of the Enterobacteriaceae family. Cinobac inhibits bacterial deoxyribonucleic acid (DNA) synthesis, is bactericidal, and is active over the entire urinary pH range. Cross resistance with nalidixic acid has been demonstrated.
| Trade Name | Cinobac |
| Availability | Discontinued |
| Generic | Cinoxacin |
| Cinoxacin Other Names | Cinoxacin, Cinoxacine, Cinoxacino, Cinoxacinum |
| Related Drugs | amoxicillin, doxycycline, ciprofloxacin, cephalexin, ceftriaxone, levofloxacin, Augmentin, nitrofurantoin, Keflex |
| Type | Oral |
| Formula | C12H10N2O5 |
| Weight | Average: 262.2182 Monoisotopic: 262.05897144 |
| Protein binding | 60 to 80% |
| Groups | Approved, Investigational, Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
For the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: Escherichia coli, Proteus mirabilis, Proteus vulgaris, Klebsiella species (including K. pneumoniae), and Enterobacter species.
How Cinobac works
Evidence exists that cinoxacin binds strongly, but reversibly, to DNA, interfering with synthesis of RNA and, consequently, with protein synthesis. It appears to also inhibit DNA gyrase. This enzyme is necessary for proper replicated DNA separation. By inhibiting this enzyme, DNA replication and cell division is inhibited.
Toxicity
Oral, subcutaneous, and intravenous LD50 in the rat is 3610 mg/kg, 1380 mg/kg, and 860 mg/kg, respectively. Oral, subcutaneous, and intravenous LD50 in the mouse is 2330 mg/kg, 900 mg/kg, and 850 mg/kg, respectively. Symptoms following an overdose of cinoxacin may include gastrointestinal effects such as anorexia, nausea, vomiting, epigastric distress, and diarrhea; the severity of the epigastric distress and diarrhea are dose-related. Headache, dizziness, insomnia, photophobia, tinnitus, and a tingling sensation have also been reported in some patients.
Cinobac multivitamins interaction
[Moderate] ADJUST DOSING INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.
Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.
The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.
The bioavailability of ciprofloxacin has been reported to decrease by as much as 90% when administered with antacids containing aluminum or magnesium hydroxide.
When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.
When coadministered with Suprep Bowel Prep (magnesium Please consult individual product labeling for specific recommendations.
Cinobac Drug Interaction
Moderate: celecoxib, celecoxibUnknown: amikacin, amikacin, lvp solution, lvp solution, lvp solution with potassium, lvp solution with potassium, ascorbic acid, ascorbic acid
Cinobac Disease Interaction
Major: CNS disorders, myasthenia gravis, peripheral neuropathy, tendonitis
Elimination Route
Rapidly absorbed after oral administration. While concurrent food intake may delay the drug absorption, the total drug absorption is not affected.
Half Life
While the mean serum half-life is 1.5 hours, the half-life may exceed 10 hours in case of renal impairment.
Innovators Monograph
You find simplified version here Cinobac
